drugset / Trial / NCT00204568
Trofosfamide Versus Adriamycin in Elderly Patients With Soft Tissue Sarcoma (STS)
Phase 2
Unknown
117 enrolled
University Hospital Schleswig-Holstein
Arbeitsgemeinschaft fur Internistische Onkologie · collabFrench Sarcoma Group · collabGerman Sarcoma Group · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The goal of this trial is to determine whether oral continuous (metronomic) therapy with trofosfamide results in a similar rate of progression-free time after 6 months as intravenous treatment with adriamycin. In addition, the study is intended to investigate the level of toxicity associated with the two treatment regimens (safety profile).
Timeline
- Start
- 2004-08
- Primary completion
- 2013-10
- Completion
- 2013-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Doxorubicin | Other / unclassified | 60 mg/m2 | Intravenous |
| Comparator | Doxorubicin | Other / unclassified | 75 mg/m2 | Intravenous |
| Subject | Trofosfamide | Small molecule | 150 mg | Oral |
| Subject | Trofosfamide | Small molecule | 200 mg | Oral |